Background: Hospital admissions for respiratory syncytial virus infection result in large
health expenditures for Inuit infants. Palivizumab has been shown to be highly effective in …

Background: The objectives were to compare actual respiratory syncytial virus (RSV)
hospitalization rates and costs in a cohort of Inuit infants to hypothetical palivizumab …

Abstract Introduction: Canadian, Inuit, full term infants have the highest rate of respiratory
syncytial virus (RSV) infection globally, which results in substantial costs associated …

BACKGROUND/OBJECTIVE: Nunavut has the highest hospitalization rates for respiratory
syncytial virus (RSV) worldwide, with rates of 166 per 1000 live births per year< 1 year of …

Background: Prophylactic therapy with palivizumab, a humanized monoclonal antibody, has
been shown to reduce the number of respiratory syncytial virus (RSV)-related …

Aim: To investigate the cost‐effectiveness of palivizumab vs. no prophylaxis for respiratory
syncytial virus (RSV) infection in preterm infants in Sweden. Methods: A probabilistic Markov …

Abstract Background Alaska Native infants experience high rates of respiratory syncytial
virus (RSV) hospitalizations. Through 2008, Alaska administered a 7-dose (maximum) …

Objectives. To evaluate the costs and benefits of two new agents, respiratory syncytial virus
immune globulin (RSVIG) and palivizumab, to prevent respiratory syncytial virus (RSV) …

Aim To evaluate the cost-effectiveness of palivizumab prophylaxis for premature infants
born< 29 weeks in Hong Kong. Method We evaluated the hospitalization rate for respiratory …

Background: In 2015, the Quebec Ministry of Health limited palivizumab prophylaxis for
respiratory syncytial virus (RSV) in premature infants to those born at< 33 weeks gestational …